p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53
暂无分享,去创建一个
[1] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[2] R. Palmiter,et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.
[3] G. Gaidano,et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[4] T. Crook,et al. p53 is frequently mutated in Burkitt's lymphoma cell lines. , 1991, The EMBO journal.
[5] P. Meltzer,et al. Amplification of a gene encoding a p53-associated protein in human sarcomas , 1992, Nature.
[6] K. Bhatia,et al. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors. , 1992, Cancer research.
[7] T. Crook,et al. Biological activities of p53 mutants in Burkitt's lymphoma cells. , 1993, The Journal of general virology.
[8] G. Klein. Multistep evolution of B-cell-derived tumors in humans and rodents. , 1993, Gene.
[9] M. Yuille,et al. Deletions and rearrangement of CDKN2 in lymphoid malignancy. , 1995, Blood.
[10] F. Zindy,et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.
[11] G. Gaidano,et al. Intraclonal molecular heterogeneity suggests a hierarchy of pathogenetic events in Burkitt's lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] Mark J Alkema,et al. Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex. , 1997, Genes & development.
[13] Rajiv Kumar,et al. Selective deletion of exon 1β of the p19ARF gene in metastatic melanoma cell lines , 1998, Genes, chromosomes & cancer.
[14] Yue Xiong,et al. ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.
[15] Kevin Ryan,et al. The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.
[16] T. Tursz,et al. Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells , 1998, Oncogene.
[17] Ken Chen,et al. The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.
[18] Peter A. Jones,et al. The Human ARF Cell Cycle Regulatory Gene Promoter Is a CpG Island Which Can Be Silenced by DNA Methylation and Down-Regulated by Wild-Type p53 , 1998, Molecular and Cellular Biology.
[19] E. Ramsay,et al. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[20] F. Zindy,et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[21] Charles J. Sherr,et al. Nucleolar Arf sequesters Mdm2 and activates p53 , 1999, Nature Cell Biology.
[22] K. Bhatia,et al. Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis. , 1999, Cancer research.
[23] R. DePinho,et al. The INK4A/ARF locus and its two gene products. , 1999, Current opinion in genetics & development.
[24] M. Roussel,et al. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.
[25] A. Levine,et al. P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[26] K Kornfeld,et al. Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. , 1999, Genes & development.
[27] S. Lowe,et al. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. , 1999, Genes & development.
[28] L. Kedes,et al. Twist is a potential oncogene that inhibits apoptosis. , 1999, Genes & development.
[29] R. Honda,et al. Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 , 1999, The EMBO journal.
[30] Y. Taya,et al. Activation of p53 in MDM2-overexpressing cells through phosphorylation. , 1999, Biochemical and biophysical research communications.
[31] Y. Xiong,et al. Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. , 1999, Molecular cell.
[32] F. Bosman,et al. Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. , 1999, Blood.
[33] R. DePinho,et al. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus , 1999, Nature.
[34] P. Guldberg,et al. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma , 2000, Leukemia.
[35] M. Lindström,et al. Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus. , 2000, Experimental cell research.
[36] M. Roussel,et al. Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex , 2000, Molecular and Cellular Biology.
[37] J. D. Weber,et al. The ARF/p53 pathway. , 2000, Current opinion in genetics & development.
[38] A. López-Guillermo,et al. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. , 2000, The American journal of pathology.
[39] D. Bishop,et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. , 2001, Human molecular genetics.
[40] R. DePinho,et al. Efficiency Alleles of the Pctr1 Modifier Locus for Plasmacytoma Susceptibility , 2001, Molecular and Cellular Biology.